Engflag

Husren

Quick links to important sections

Husren

Husren_EN

Method of action: Analgesic, Anti-Inflammatory, Corrective Metabolism Of Bone And Cartilaginous Tissue, Other Drugs For Disorders Of The Musculo-Skeletal System

Treatment option: Glaucoma, Cataract, Corneal Transplant, Surgery, Cataract Extraction

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Husren

Quick Facts

Property Description
Active ingredient Sodium Hyaluronate (Hyaluronic Acid salt)
Form Sterile solution for injection (viscoelastic)
Pharmacological class Viscosupplement / Rheological Agent
General purpose Mechanical support and lubrication
Origin Naturally derived (Bio-fermented)

What Type of Medicine is Husren? (Definition and Classification)

Husren is a specialized pharmaceutical formulation classified primarily as a viscosupplement and rheological agent, a category of substances intended to restore or augment the fluid environment within tissues. It is supplied as a sterile solution for injection, administered parenterally, typically via intra-articular injection directly into a joint space. This distinct classification means its action is highly localized, delivering mechanical support directly to the target site. This type of product is clinically recognized for its potential to provide sustained local functional improvement.

Composition and Origin: Is Sodium Hyaluronate Natural?

The active ingredient in Husren is Sodium Hyaluronate (INN), the sodium salt of Hyaluronic Acid (HA), a high molecular weight, naturally occurring glycosaminoglycan essential to human connective tissue. Husren is a single-ingredient product suspended in a clear, highly viscous aqueous solution. Although Hyaluronic Acid is native to the body, the substance used in pharmaceutical-grade viscosupplements is commonly manufactured through a controlled bio-fermentation process to ensure high purity and a defined molecular weight. This bio-fermented origin is a key feature, resulting in a product that closely mimics the body's own native macromolecule.

General Purpose: How Husren Provides Mechanical Support

The general purpose of Husren is rooted in its viscoelasticity, meaning the solution acts both as a lubricant and a shock-absorber. By augmenting the local environment, the medicine helps improve the fluid's ability to reduce friction and absorb external force. Hyaluronic Acid preparations are used to improve the environment of affected joints. This mechanical augmentation is intended to maintain the structural integrity and homeostasis of the targeted tissue, facilitating smoother, less impeded movement.

Regulatory References

  1. Viscosupplements (NLM MeSH)

What side effects are possible with Husren?

Possible side effects and safety information

The official safety profile for Husren (Sodium Hyaluronate viscosupplement) is primarily characterized by localized, transient reactions at the site of administration, with less frequent systemic events. Regulatory agencies classify side effects according to frequency using terms such as Very Common, Common, Uncommon, and Rare.

Adverse Reaction Classifications

Category Common Reactions System-Organ Class Involved
Local/Injection Site Pain, Swelling, Joint Effusion, Warmth, Stiffness General Disorders and Administration Site Conditions
Musculoskeletal Arthralgia (joint pain) Musculoskeletal and Connective Tissue Disorders
Systemic Headache, Dizziness, Nausea Immune System/Skin Disorders

Local adverse reactions are generally transient and resolve within a few days following the injection. The most frequently reported events are pain and swelling of the injected joint, classified as Common or Very Common in regulatory data.

Serious Reactions and Safety Constraints

While rare, Serious Adverse Reactions documented in regulatory sources include anaphylactic/anaphylactoid reactions (severe allergic events) and episodes of acute joint inflammation that require acute medical management. The product is contraindicated when pre-existing infection or severe inflammation is present in the joint or surrounding skin, or in patients with known hypersensitivity to the preparation. Safety has not been established in pediatric patients, pregnant women, or nursing mothers, and use in these populations is not recommended. Furthermore, intravascular injection must be avoided, and regulatory documents advise against using certain quaternary ammonium salt-containing disinfectants for skin preparation due to material incompatibility.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents for Husren (Sodium Hyaluronate injection) often note that systemic overdose is not applicable (NA) due to its local administration. The documented overdose profile instead focuses on severe, immediate post-injection events and systemic risks.

Overdose Manifestations and Risks

Classification Documented Findings in Official Labeling
Exaggerated Local Effects Severe pain and severe swelling at the injection site, or joint effusion [Source: FDA Prescribing Information].
Severe Outcomes Anaphylactoid reactions (allergic symptoms, including transient hypotension), and the critical procedural risk of intra-articular infection (septic arthritis) [Source: Regulatory Warnings].

Emergency Actions Required

Regulatory warnings mandate that a patient seek immediate medical attention for any occurrence of severe pain, pronounced swelling, or signs of a systemic allergic reaction (e.g., rash, hives, or breathing difficulty).

Supportive Management and Antidote

For localized symptoms, initial official instructions include resting the affected joint and applying ice locally. In cases of severe systemic events, general symptomatic and supportive treatment is necessary, and official labeling confirms that no specific antidote is known for this substance. Hospital monitoring may be required for managing severe systemic complications.

Therapeutic Uses of Husren

What Husren Treats: Main Uses and Benefits

Husren is applied across domains where additional symptomatic support is needed in situations involving certain distressing symptoms. These applications are relevant when supportive symptom management is appropriate.

Easing Symptomatic Episodes

This domain is commonly used when symptoms related to heightened physiological activity appear suddenly or fluctuate, resulting in symptoms that create noticeable functional strain. Husren offers symptomatic relief that may help patients cope more steadily with difficult episodes. It is commonly used to help with symptom clusters that may become intense or disruptive, especially those that interfere with daily functioning.

“Husren supports general well-being during symptomatic phases and may help improve day-to-day comfort during periods of heightened symptoms.”

Supporting Fluctuating Symptoms

Husren is relevant in conditions characterized by periods of heightened symptoms or recurrent or episodic manifestations. It is often used when symptoms intensify and supportive relief is needed, as it assists in managing symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load.

Quick Fact: Assistance with Acute Discomfort Husren is commonly used to help with symptoms associated with acute or episodic changes and may assist with maintaining functional stability when symptoms are more noticeable.

Regulatory References

  1. NIH StatPearls overview of Symptomatic Medications

Eligibility and Restrictions for Use

Who Can and Cannot Use Husren?

The eligibility for Husren, a localized viscosupplement, is defined by absolute prohibitions and specific data limitations outlined in official regulatory documents. Approved use is established in the adult population (typically 18 years of age and older).

Population Status Regulatory Statement
Allowed Adults (typically 18 years of age and older) for established use.
Contraindicated Patients with known hypersensitivity to Sodium Hyaluronate or any component.
Patients with infections or skin diseases at the intended injection site, or with an active joint infection.
Not Recommended Pediatric patients (under 18 or 21 years) and pregnant or lactating women. Safety and effectiveness in these groups have not been established.

Use requires caution in patients with evidence of venous or lymphatic stasis in the affected limb. Furthermore, the official prescribing information requires that any severe acute inflammation or excessive joint effusion is addressed before Husren is administered. There are typically no specific eligibility restrictions related to systemic organ function, such as severe renal or hepatic impairment, consistent with the medicine's highly localized action.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Husren (Sodium Hyaluronate) is a specialized viscosupplement administered via local intra-articular injection. Consequently, its official interaction profile is defined by local, procedural restrictions rather than systemic drug-drug interactions.

Category Official Regulatory Documentation
Interacting Product Category Disinfectants containing quaternary ammonium salts; Other intra-articular injectables.
Interaction Mechanism/Basis Physicochemical precipitation of Sodium Hyaluronate; Lack of established safety/effectiveness for co-administration.
Interaction-Related Restriction Prohibited use of specified disinfectants for skin preparation; Unestablished safety for concurrent use with other joint injectables.

Official Regulatory Statements

  • Co-administration of Husren is prohibited with disinfectants containing quaternary ammonium salts because the Sodium Hyaluronate can undergo a physicochemical precipitation. This is a mandatory constraint related to the preparation of the injection site.
  • Official labeling states that the safety and effectiveness of using Husren concomitantly with other intra-articular injectables (such as corticosteroids or local anesthetics) have not been established.
  • No systemic drug–drug interactions, including those involving metabolic enzymes, transporters, food, alcohol, or supplements, are documented in official regulatory labeling.

This official interaction structure confirms that the concerns are confined to the immediate administration environment and the formal status of co-administration with other substances intended for the joint space.

Mechanism of Action

Husren is a monoclonal antibody that acts as an inhibitor of the Receptor Activator of NF-κB Ligand (RANKL).

It binds specifically to both soluble and membrane-bound forms of RANKL, thereby sterically preventing RANKL from activating its cognate receptor, RANK, which is located on the surface of pre-osteoclasts and mature osteoclasts. This molecular blockade disrupts the intracellular signaling cascade necessary for osteoclast differentiation, maturation, function, and survival.

By inhibiting the formation and activity of osteoclasts, Husren modulates the physiological balance between bone resorption and bone formation. The resulting decreased bone resorption leads to a reduction in biochemical markers of bone turnover at a systemic level.

Dosage and Administration Information

How to Use Husren: Official Administration Guidelines

Husren is a specialized viscosupplement whose administration is defined by a strict, procedural protocol, focusing solely on the principles of use and professional oversight.

Administration Scope

Entity Instruction
Route of administration Exclusively via intra-articular injection, delivered directly into the joint space.
Dosing schedule Administration follows a defined course of treatment of one, three, or five injections, with the active ingredient amount per injection ranging from approximately 20 mg to 88 mg.
Frequency pattern For multi-injection regimens, the product is administered once weekly to complete the course, establishing an intermittent use pattern.

Procedural and Handling Instructions

Entity Procedural Constraint
Supervision The procedure must be performed by or under the immediate supervision of a healthcare professional.
Pre-Injection Steps Strict aseptic technique is mandatory, and any significant joint effusion (excess fluid) must be removed prior to injection.
Product Handling Do not use skin disinfectants containing quaternary ammonium salts for preparation, as this may cause the Sodium Hyaluronate to precipitate. The syringe is for single use only.

Use Patterns and Population Limits

Usage protocols dictate that the total treatment duration for a course ranges from one to five weeks. Repeat courses (retreatment) are used, often requiring an interval of six months or more between cycles. Furthermore, safety and effectiveness have not been established for use in pediatric patients.

Recent Clinical Evidence

Research evidence / Overview of studies

The drug has been the subject of research, primarily examining its potential role in the context of research for specific inflammatory conditions. Early studies in animal models and initial human trials provided data, leading to the current Phase 3 trials. This section is an overview of research and is not direct medical advice.

Key Studies on Efficacy

A large 2022 randomized controlled trial (RCT) in 400 patients with chronic knee inflammation reported on pain reduction and stiffness. The study also noted observed changes in key inflammatory biomarkers over a 6-month period, compared to placebo.

Research also investigated the time to onset of an effect in patients experiencing acute flare-ups of conditions like gout. A 2023 meta-analysis of three studies, encompassing 850 total patients, compared the drug's effect by comparing reported rates of a 50% reduction in pain within 48 hours when compared to other studied treatments.

Safety and Tolerability Profile

Initial research examined tolerability for the study duration and populations reported. The most common side effects observed were mild, including temporary digestive discomfort. Studies explored the potential for interactions, noting that combining the drug with certain blood thinners may carry risks.

A 2021 study specifically investigated drug interactions and noted observed risks or exclusions related to individuals with pre-existing heart conditions in the trial population. The findings indicated the drug was tolerated by the patient populations studied.

How should Husren be stored and disposed of?

The storage and disposal of Husren (Sodium Hyaluronate viscosupplement) must strictly follow the conditions specified in the official regulatory labeling.

Official Storage Requirements

Requirement Category Official Regulatory Statement
Temperature Store the product at controlled room temperature, below 77°F (25°C).
Prohibited Environment DO NOT FREEZE the solution; it must be protected from freezing.
Protection Keep Husren in the original packaging to protect it from light.
Integrity Do not use the syringe if the sterile packaging is opened or damaged.

Handling and Disposal Rules

  • Single-Use and Stability: The syringe is for single use only. The contents must be used immediately once the packaging has been opened, and the product must not be used after its printed expiration date.
  • Disposal: Any unused portion of the medicine must be discarded after the procedure according to local medical waste guidelines.
  • Child Safety: The product must be kept out of the sight and reach of children at all times.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagJapan

Equivalent of Husren found in:

A-Z Index: